Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARROW: Selonsertib in PAH
NCT02234141Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Nov 2014
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of selonsertib in pulmonary arterial hypertension (PAH), sponsored by Gilead Sciences. Started Nov 2014; status: completed.
02
Drugs
selonsertib
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02234141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02234141.